CD96 Antigen Binding Proteins for Immune Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for improved antigen binding proteins that target CD96 for the treatment of diseases, particularly cancer, as existing knowledge on CD96 function is limited and current therapies are inadequate.

Innovation Solution

Development of CD96 binding proteins, nucleic acid constructs, expression vectors, and recombinant host cells to produce these proteins, which are administered therapeutically to modulate CD96 activity and enhance immune responses against cancer cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CD96 binding proteins are developed to inhibit CD96 function and enhance immune responses, then treatment outcomes for cancer are improved, but the complexity of the therapeutic approach increases

Engineering Contradiction:

Improvetreatment outcomesVSAvoidtherapeutic approach

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent develops CD96 binding proteins (antibodies and antibody fragments) as intermediary molecules that specifically bind to CD96 on immune cells and tumor cells. These binding proteins act as mediators to block the CD96-CD155 interaction, thereby enhancing immune responses against cancer without requiring complex combination therapies or modifying the immune system fundamentally

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention utilizes parameter changes in the binding affinity and specificity of the developed CD96 binding proteins. By optimizing the affinity constants and binding characteristics of these proteins, the patent achieves effective CD96 inhibition and enhanced immune activation with a relatively simple monoclonal antibody approach rather than complex multi-component systems

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If existing knowledge on CD96 function is limited and current therapies are inadequate, then there is a need for improved antigen binding proteins, but the risk of treatment failure increases

Engineering Contradiction:

Improveantigen binding proteinsVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent segments the therapeutic approach by developing not only full-length antibodies but also antibody fragments (such as Fab, scFv, and other truncated forms) that specifically bind to CD96. This segmentation allows for multiple therapeutic options with different pharmacokinetic and pharmacodynamic properties, increasing adaptability while maintaining treatment effectiveness through selection of the most appropriate fragment type for each clinical scenario

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The developed CD96 binding proteins exhibit multi-functionality by being able to: (1) block CD96-CD155 interaction, (2) enhance immune cell activation, (3) induce antibody-dependent cellular cytotoxicity (ADCC), and (4) serve as diagnostic markers. This universality increases adaptability across different cancer types and treatment scenarios while improving reliability through multiple mechanisms of action

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP4034562B1Antigen binding proteins

Publication Date: 2025.10.29 GLAXOSMITHKLINE INTPROP DEV LTD

Figure 1
Figure 2a~2c
Figure 3

AI summary

The present disclosure relates to compositions for treating CD96 mediated diseases, and related methods.